Snapshot · Regeneron Pharmaceuticals, Inc. (REGN)

Data as of 2026-09-01T11:01:17.917Z

Fundamentals check

Market cap

$82.3B

P/E (TTM)

19.1

Gross margin

84.9%

Net margin

27.9%

ROE

13.8%

R&D / revenue

41.6%

Dividend yield

0.5%

FCF yield

4.3%

Latest dividend: $0.94/share (ex-date 2026-08-18, quarterly)

Summary

Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients. Furthermore, Regeneron provides Inmazeb for infections caused by Zaire ebolavirus; ARCALYST, an injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome; and ZALTRAP, an intravenous infusion used in the treatment of metastatic colorectal cancer. In addition to its existing product lineup, the company is actively engaged in developing novel product candidates aimed at addressing unmet medical needs in areas such as ocular diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious diseases, rare diseases, cancer, pain management, and hematologic conditions. Regeneron maintains extensive collaboration and licensing agreements with a diverse range of partners, including Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc., Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd. It also holds agreements with entities such as the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, Inc., the Biomedical Advanced Research Development Authority, and AstraZeneca PLC. The company was founded in 1988 and its corporate headquarters are situated in Tarrytown, New York.

How it makes money

Revenue mix, latest fiscal year

• Collaboration Revenue51.1%
• Product44%
• Product and Service, Other4.9%

Recent Events

• 2026-08-31T05:39:14.000Zpositive

  Corient Private Wealth LP Purchases Shares of 14,670 Regeneron Pharmaceuticals, Inc. $REGN

  可能与机构增持相关，股价短期内出现小幅上涨。

  Source: defenseworld.net

• 2026-08-31T05:39:14.000Zpositive

  Corient Private Wealth LP Reduces Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

  虽为减持但市场信号含糊，可能与组合调整相关，股价呈现小幅上涨趋势。

  Source: defenseworld.net

• 2026-08-25T09:01:27.000Zpositive

  Regeneron: Why I Still See Upside After The Rally

  分析观点表明潜在上涨机会，可能与公司基本面改善相关。

  Source: seekingalpha.com

• 2026-08-22T03:51:42.000Zpositive

  Bank of New York Mellon Corp Buys New Stake in Regeneron Pharmaceuticals, Inc. $REGN

  机构增持信号，市场对股票需求可能增加。

  Source: defenseworld.net

• 2026-08-22T03:10:40.000Zpositive

  Allworth Financial LP Buys Shares of 2,530 Regeneron Pharmaceuticals, Inc. $REGN

  新进机构买入，可能与投资者兴趣回暖相关。

  Source: defenseworld.net

• 2026-08-21T04:39:00.000Zneutral

  Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - REGN

  法律诉讼新闻可能影响情绪，但当前信息未显示因果关系。

  Source: prnewswire.com

• 2026-08-20T11:41:07.000Zpositive

  Regeneron Secures FDA Approval for Rare Genetic Disorder Drug

  药物获批为潜在利好，市场可能反应积极，需关注实际影响。

  Source: zacks.com

• 2026-08-19T16:05:00.000Zneutral

  Regeneron Announces Investor Conference Presentations

  投资者会议公布信息可能影响情绪，但短期方向不确定。

  Source: globenewswire.com

• 2026-08-19T14:17:37.000Znegative

  US FDA approves Regeneron's rare bone disorder drug

  FDA 批准消息本应利好，短期股价下降可能由其他因素驱动，需谨慎解读。

  Source: reuters.com

• 2026-08-19T00:00:00.000Zpositive

  Price move: REGN rose 3.8%

  REGN 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-08-18T03:55:14.000Zpositive

  BlackRock Inc. Makes New $5.68 Billion Investment in Regeneron Pharmaceuticals, Inc. $REGN

  大型机构新增持股，可能对市场情绪造成积极影响。

  Source: defenseworld.net

• 2026-08-17T05:05:34.000Zpositive

  Focus Partners Advisor Solutions LLC Invests $1.35 Million in Regeneron Pharmaceuticals, Inc. $REGN

  新进机构投资，或影响买盘情绪。

  Source: defenseworld.net

• 2026-08-17T04:19:19.000Zpositive

  AMG National Trust Bank Makes New $1.22 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN

  新买入潜在提升需求端支撑，市场反应积极。

  Source: defenseworld.net

• 2026-08-12T03:39:25.000Zneutral

  E. Ohman J or Asset Management AB Has $2.39 Million Position in Regeneron Pharmaceuticals, Inc. $REGN

  机构持仓变动信息可能影响情绪，但短期方向不明确。

  Source: defenseworld.net

• 2026-08-11T11:30:22.000Zpositive

  REGN Soars 21.9% in a Month: Buy, Sell or Hold the Stock?

  分析师观点显示上涨潜力，或与近期表现相关。

  Source: zacks.com

• 2026-07-30T00:00:00.000Zpositive

  REGN filed 10-Q

  可能与该次 10-Q/相关信息披露有关，市场对新闻产生积极反应的迹象。

  Source: SEC EDGAR

• 2026-07-30T00:00:00.000Znegative

  REGN filed 8-K

  公告性信息披露，短期股价波动方向不确定，需进一步信息确认。

  Source: SEC EDGAR

• 2026-07-30T00:00:00.000Zpositive

  Price move: REGN rose 6.2%

  REGN 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-07-28T00:00:00.000Zpositive

  Price move: REGN rose 4.2%

  REGN 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-07-02T00:00:00.000Zpositive

  Price move: REGN rose 4.7%

  REGN 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

Analyst view

Avg price target $808.14 from 14 analysts (last quarter)

Insider & Congress activity

Open-market trades only; grants and exercises excluded

• 2026-08-10SellZoghbi Huda Y(director)800 shares
• 2026-08-10SellGuarini Kathryn(director)400 shares
• 2026-07-02SellRYAN ARTHUR F(director)200 shares

US Congress trading disclosures

• 2026-03-27Alan ArmstrongPurchase$1,001 - $15,000

订阅每日简报

每个交易日开盘/收盘后，中文市场简报直达邮箱。免费，随时退订。

本内容仅为信息整理，不构成任何投资建议。